HUMAW
Price:
$1.99
Market Cap:
$634.81M
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery...[Read more]
Industry
Biotechnology
IPO Date
Stock Exchange
NASDAQ
Ticker
HUMAW
According to Humacyte, Inc.’s latest financial reports and current stock price. The company's current ROE is -1154.12%. This represents a change of 2.50% compared to the average of -44.31% of the last 4 quarters.
The mean historical ROE of Humacyte, Inc. over the last ten years is -155.43%. The current -1154.12% ROE has changed 642.55% with respect to the historical average. Over the past ten years (40 quarters), HUMAW's ROE was at its highest in in the June 2020 quarter at 1.69%. The ROE was at its lowest in in the March 2021 quarter at -406.02%.
Average
-155.43%
Median
19.62%
Minimum
-817.78%
Maximum
54.92%
Discovering the peaks and valleys of Humacyte, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 78.76%
Maximum Annual ROE = 54.92%
Minimum Annual Increase = -1588.98%
Minimum Annual ROE = -817.78%
Year | ROE | Change |
---|---|---|
2023 | -817.78% | -1588.98% |
2022 | 54.92% | 78.76% |
2021 | 30.72% | 56.61% |
2020 | 19.62% | -130.36% |
The current ROE of Humacyte, Inc. (HUMAW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-244.04%
5-year avg
-155.43%
10-year avg
-155.43%
Humacyte, Inc.’s ROE is greater than Humacyte, Inc. (-1154.12%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Quantum-Si incorporated (-34.01%), greater than Celularity Inc. (-279.32%), less than Roivant Sciences Ltd. (102.72%),
Company | ROE | Market cap |
---|---|---|
-1154.12% | $634.81M | |
2.18% | $2.82K | |
-34.01% | $115.90M | |
-279.32% | $31.66M | |
102.72% | $8.80B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Humacyte, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Humacyte, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Humacyte, Inc.'s ROE?
How is the ROE calculated for Humacyte, Inc. (HUMAW)?
What is the highest ROE for Humacyte, Inc. (HUMAW)?
What is the 3-year average ROE for Humacyte, Inc. (HUMAW)?
What is the 5-year average ROE for Humacyte, Inc. (HUMAW)?
How does the current ROE for Humacyte, Inc. (HUMAW) compare to its historical average?